Recent NMR studies by Harper *et al*. revealed the mechanism of a protein light switch in *Avena sativa* Phototropin1[@R6],[@R12]: a flavin-binding LOV2 domain interacts with a C-terminal helical extension (Jα) in the dark. Photon absorption leads to formation of a covalent bond between Cys450 and the flavin chromophore, causing conformational changes that result in dissociation and unwinding of the Jα helix. We fused the complete LOV2-Jα sequence (404--547) to the N-terminus of a constitutively active Rac1, anticipating that the LOV domain in its closed conformation would block the binding of effectors to Rac1, and that light-induced unwinding of the Jα helix would release steric inhibition, leading to Rac1 activation ([Fig. 1a](#F1){ref-type="fig"}). Sampling of different junctional sequences in pull down assays revealed that connecting Leu546 of LOV2-Jα to Ile4 of Rac1 led to substantial reduction in Rac1 binding to its effector PAK ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}). To ensure that the photoactivatable Rac1 would induce no dominant negative effects and that its activity would not be subject to upstream regulation, mutations were introduced to abolish GTP hydrolysis and diminish interactions with nucleotide exchange factors, guanine nucleotide dissociation inhibitors (Q61L) and GTPase activating proteins (E91H and N92H) ([Supplementary: Fig. S2](#SD1){ref-type="supplementary-material"} and "Characterization of Rac1 constructs"). This resulted in the photoactivatable analogue of Rac1 (PA-Rac1) used in the following studies. Pull down assays showed that PA-Rac1 has greatly reduced affinity for its effector protein PAK in the dark, as does a PA-Rac1 construct containing a light-insensitive LOV2 mutation (C450A)[@R13]. Effector binding was restored in a PA-Rac1 construct containing a LOV2 mutant (I539E)[@R14] that mimics the unfolded 'lit state' ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. S1b](#SD1){ref-type="supplementary-material"}). Isothermal titration experiments indicated that the dark and lit state mutants of PA-Rac1 differed 10-fold in effector binding (200 nM versus 2 µM) ([Supplementary Fig. S3 and Table S1](#SD1){ref-type="supplementary-material"}), with lit state effector affinity similar to that of native Rac[@R15].

Activation of PA-Rac1 was examined in HeLa cells expressing a YFP fusion of PA-Rac1 to gauge expression level. The cells remained quiescent when illuminated with wavelengths longer than flavin absorbance (515, 568 or 633 nm, data not shown), but within seconds after switching to 458 nm, lamellipodial protrusions and membrane ruffles appeared around the cell edges ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Movie S1](#SD1){ref-type="supplementary-material"}). To show that this effect was due to PA-Rac1, kymograms were used to quantify maximum protrusion length; Irradiation of PA-Rac1 elicited protrusions that were four times as long as those seen in cells expressing either LOV domain alone or the light-insensitive PA-Rac1-C450A mutant ([Supplementary Fig. S4](#SD1){ref-type="supplementary-material"}). An important advantage of PA-Rac1 is its ability to precisely control the subcellular location of Rac activation. We first examined this in mouse embryo fibroblasts (MEF) stably expressing PA-Rac1, and cultured without serum to minimize cell activity prior to irradiation. Irradiation of 20 µm spots at the cell edge generated large protrusions clearly localized next to the point of irradiation ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Movie S2](#SD1){ref-type="supplementary-material"}). Repeated irradiation led first to ruffles and then to protrusion. YFP-actin, YFP-PAK, and YFP-Arp3 revealed actin polymerization at the edge of the Rac-induced protrusions with associated translocation of downstream effectors, and induction of localized PAK phosphorylation was shown by immunostaining ([Supplementary Fig S5,6 and Movies S3,4](#SD1){ref-type="supplementary-material"}). Movement of a laser spot to different positions led to cessation of ruffling or protrusion at the initial irradiation position and new activities appearing where the laser spot was brought to rest (HeLa cells, [Supplementary Movie S5](#SD1){ref-type="supplementary-material"}), demonstrating reversible activation. In MEF cells, more prone to movement than HeLa, complex shape changes were produced by 'painting' the cell with the laser spot ([Supplementary Movie S6](#SD1){ref-type="supplementary-material"}). The area of protrusions in MEF cells was dependent on light dosage, indicating the valuable ability to control the level of Rac1 activation ([Supplementary Fig. S7](#SD1){ref-type="supplementary-material"}). PA-Rac1 diffusion was analyzed using FRAP (fluorescence recovery after photobleaching) and using PA-Rac1 tagged with photoactivatable GFP[@R16] ([Supplementary Fig. S8 and Movies S7,8](#SD1){ref-type="supplementary-material"}), indicating that PA-Rac1 diffuses more slowly than cytosolic proteins, likely because it is membrane bound (10 µm spot, FRAP D=0.55 µm^2^/s or t~1/2~= 12.1s; PA-GFP t~1/2~=14.6 s). The half life of dark recovery for PA-Rac1 was determined to be 43s at room temperature. Simulation using this value indicated that, for two adjacent 10-µm spots, the unirradiated spot will achieve at most 7.5% the activation of the irradiated region ([Supplementary Fig. S8c](#SD1){ref-type="supplementary-material"}). Together these studies validate PA-Rac1 as a robust, genetically encoded and reversible caged protein effective in living cells.

We used PA-Rac1 to ask whether localized Rac activation is sufficient to specify cell polarity. In MEF cells, activating Rac1 at one spot near the cell edge not only generated protrusion locally, but also produced retraction on the opposite side of the cell ([Fig. 2a](#F2){ref-type="fig"} and [Supplementary Movie S9](#SD1){ref-type="supplementary-material"}). To test whether this cross-cell coordination was due to a gradient of Rac1 activity, we fused the LOV domain to a dominant negative mutant of Rac1 using the same linkage as in PA-Rac1. Irradiation of this PA-Rac1-T17N led to nearby retraction rather than protrusion, and now generated protrusion in other areas of the cell ([Fig 2a](#F2){ref-type="fig"} and [Supplemental Movies S10,11](#SD1){ref-type="supplementary-material"}). The ability of Rac1 alone to control polarized movement was confirmed by repeated irradiation at the cell edge, which could be used to produce prolonged cell movement by generating consistent coordinated extension and retraction (MEF cells: [Fig. 2b](#F2){ref-type="fig"} and [Supplemental Movie S12](#SD1){ref-type="supplementary-material"}; HEK293 cells: [Supplemental Movie S13](#SD1){ref-type="supplementary-material"}). In contrast to MEF and HEK293 cells, HeLa cells showed localized protrusion but could not be induced to retract or move simply by activating Rac ([Supplemental Movie S3](#SD1){ref-type="supplementary-material"}), indicating that Rac-induced motility is subject to modulation by other pathways.

PA-Rac1 enabled control of Rac1 activity without the prior cellular compensation seen with other techniques, i.e. mutation or altered expression. Using this advantage, we examined the role of myosin, a key mediator of actin-based contractility, in Rac-induced motility. Global inhibition of myosin activity using the myosin ATPase inhibitor blebbistatin or the myosin light chain kinase inhibitor ML-7 strongly affected Rac's ability to specify the direction of cell movement, but minimally affected Rac-induced protrusion ([Fig. 2c,d](#F2){ref-type="fig"}). Myosin may mediate Rac's control of directionality through induction of tail retraction[@R17], contraction of the cell cortex to direct protrusive force[@R18], or coupling of actin to adhesions differently at the front and rear[@R19]. In contrast, inhibition of PAK was found to strongly affect Rac-induced protrusion ([Supplementary Fig. S9](#SD1){ref-type="supplementary-material"}). Inhibition of the Rho-activated kinase ROCK using Y27632 suggested a role for ROCK in Rac-induced protrusion, but these results must be interpreted with caution due to known off-target effects[@R20].

Where and how Rac regulates Rho *in vivo* remains largely unknown; this was examined by using PA-Rac1 together with a RhoA biosensor[@R8]. Localized activation of Rac1 led to immediate inhibition of RhoA, and this inhibition spread outward from the irradiated spot ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Movie S14](#SD1){ref-type="supplementary-material"}). This was not simply an artifact of biosensor photobleaching, as irradiating the photo-inactive C450M mutant ([Fig. 2c](#F2){ref-type="fig"}) of PA-Rac1 led to localized biosensor photobleaching and recovery, but no prolonged local inhibition or wave of inhibition ([Fig. 3a](#F3){ref-type="fig"}). There were striking differences between constitutive MEF protrusions and protrusions induced by pulsed PA-Rac1 irradiation. In contrast to constitutive protrusions, RhoA activity was greatly reduced in protrusions induced by PA-Rac ([Fig. 3b](#F3){ref-type="fig"}). Inhibition of RhoA appears to be compartmentalized or controlled kinetically when Rac is activated in the context of normal motility, as both active Rac and active Rho are seen at the leading edge[@R7],[@R8],[@R21]. PA-Rac activation led to large ruffles moving from the site of irradiation rearwards towards the nucleus ([Supplementary Movie S15](#SD1){ref-type="supplementary-material"}), suggesting that Rac regulates rearwards membrane flow. In control experiments, irradiation of cells expressing the photo-inactive C450M mutant did not produce polarized ruffling or show reduced RhoA activity (data not shown).

To understand the structural basis of the PA-Rac1 switch for future application to other proteins, we performed Rosetta structure prediction simulations[@R22] on several LOV2-Rac1 constructs, and determined high-resolution crystal structures of photo-active and inactive PA-Rac1 in the dark state. The crystal structures confirmed that the LOV domain occludes effector binding in the dark state ([Fig. 4a](#F4){ref-type="fig"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). LOV-Jα adopted a closed conformation that superimposes with the recently published structure of isolated LOV-Jα[@R23]. In the conformational ensemble predicted by simulations of the dark state, the effector binding site of Rac was sterically blocked by the LOV domain in a majority of the low energy models ([Supplementary Tables S3--5 and Figs. S10--13](#SD1){ref-type="supplementary-material"}). Consistent with pull down assays ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}), adding or removing even one residue from the connection between LOV and Rac resulted in conformational ensembles with exposed effector binding sites. In the dark state, Rac was seen to form an extensive interface with the LOV domain ([Fig. 4b](#F4){ref-type="fig"}), occluding Rac binding interactions. Given the substantial structural similarity between Rac1 and Cdc42, we hypothesized that the LOV domain could also be used to cage Cdc42. However, the linkage used for PA-Rac1 failed to reduce Cdc42 binding to PAK ([Fig. 4c](#F4){ref-type="fig"} and [Supplementary Fig. S1d](#SD1){ref-type="supplementary-material"}). Using the PA-Rac1 crystal structure as a template, a model was built of the Cdc42-LOV dark state. At the interface between Rac and LOV a hydrophobic cluster is formed between residues Phe37 and Trp56 from Rac and Leu422, Pro423, Ile428, Tyr508 and Leu546 from LOV. Consistent with this being a weak, non-evolved interaction, most of the hydrogen bonding potential at the Rac-LOV interface is satisfied by buried and partially buried water molecules instead of inter-domain hydrogen bonds ([Fig 4b](#F4){ref-type="fig"}). This interface model was used to identify a mutation to Cdc42, F56W at the Rac-LOV interface, that was predicted to stabilize the dark state. Pull down assays showed that this mutation substantially improves dark state inhibition of PAK binding, and produces differential affinity for Cdc42 effector in the dark versus the lit state ([Fig. 4d](#F4){ref-type="fig"}). In living cells, irradiation of the mutated PA-Cdc42 led to production of filopodia and in some cases protrusions and/or ruffles, consistent with Cdc42 induction of filopodia and activation of Rac[@R24] ([Supplementary Fig. S14](#SD1){ref-type="supplementary-material"} and [Supplementary Movie S16](#SD1){ref-type="supplementary-material"}). These results argue that PA-Rac1 can serve as a blueprint for engineering other caged GTPases.

In summary, we have engineered genetically-encoded photoactivatable Rac1 analogs that enable precise spatial and temporal control of Rac activity in live cells, with reversible activation at 458 or 473 nm. Localized Rac activation or deactivation was sufficient to generate polarized cell movement. Rac could be activated without cellular compensation, enabling us to probe the role of myosin and PAK in Rac-mediated motility. Spatially-regulated Rac inhibition of Rho was demonstrated in living cells. Structural studies indicate that a non-evolved interaction at the Rac-LOV interface can be engineered to cage other GTPases. This study and other recent work[@R25]--[@R28] show that coupling genetically encoded light-modulated domains to other proteins provides a versatile new route to control protein activities in living cells.

METHODS SUMMARY {#S1}
===============

Imaging experiments were conducted on an Olympus FluoView 1000 laser scanning confocal microscope and an Olympus IX81-ZDC inverted microscope. Biosensor imaging was performed as previously described[@R8],[@R29]. Simultaneous biosensor imaging and activation of PA-Rac was achieved using a MAG Biosystems FRAP-3D add-on (Photometrics) for galvanometer control of laser position. Detailed materials and methods are included in the [supplementary information](#SD1){ref-type="supplementary-material"}.
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![Engineering and *in vivo* characterization of a photoactivatable Rac1 (PA-Rac1)\
**a**, Cartoon representation of PA-Rac1 design. **b**, Pulldown of PA-Rac1 constructs with PAK in the dark. Truncations of LOV and Rac at their linkage point were tested: *539--547, in red* = terminal amino acid of Jα; *2--4, in green* = first residue of Rac1. 546−4 showed the strongest inhibition; PA-Rac1 = 546−4, Q61L/E91H/N92H; -*C450A*, light-insensitive mutant; -*I539E*, lit state mutant. Pulldown by constitutively active (Q61L) and dominant negative (T17N) mutants are included for comparison with PA-Rac1. **c**, Whole cell irradiation of a HeLa cell expressing PA-Rac1. (minutes after irradiation, DIC, short axis of box = 20 µm). **d**, Spatial control of Rac1 activity. A 20-µm circle (red) was irradiated every 60 seconds in serum-starved MEF cells. Solid line = cell border at time 0, dotted line = 10 minutes after initial light pulse. Little movement of the cell border was detected, except adjacent to the point of irradiation. The kymograph (taken using white line, 20 µm), shows the initial formation of ruffles after each pulse, followed by protrusion (arrowheads = irradiation pulses).](nihms129300f1){#F1}

![Localized activation or inactivation of PA-Rac1 induces myosin-dependent migration\
**a**, Protrusion/retraction map after a single pulse of activating illumination. MEFs expressing PA-Rac1 (*left*) generated protrusions at the site of irradiation (red) and retraction at the opposite side of the cell (blue) (in all 50 cells studied). Irradiation of the dominant negativeT17N mutant of PA-Rac1 (*right*) produced retraction near the point of irradiation, with protrusion in area(s) other than the site of irradiation (in all 25 cells studied). **b**, Repeated activation of PA-Rac1 at the cell edge induces directional migration. (MEF, 2-minute intervals, avg. 0.8 microns/pulse, n = 6). **c**, Localized activation of PA-Rac1 in the presence of ML-7 (MLCK inhibitor, 1 µM), Blebbistatin (Myosin II ATPase inhibitor, 1 µM), or Y-27632 (ROCK inhibitor, 10 µM). Protrusions analyzed as in panel a. **d**, Effect of myosin or ROCK inhibition on the ability of Rac1 to specify the direction of movement. The cosine of the angle between two lines (from the irradiation spot to the cell centroid at time 0, from the centroid at time 0 to the centroid at the end of the experiment) indicated how much the cell deviates from the direction specified by local irradiation. (panels c and d, n \> 25; means +/− 95% confidence intervals; throughout [figure 3](#F3){ref-type="fig"} irradiation at 458 nm, Ø = 10 µm).](nihms129300f2){#F2}

![Inhibition of RhoA by PA-Rac1\
**a**, HeLa cells expressing RhoA biosensor and either PA-Rac1 or its C450M photo-inactive mutant, illuminated in a 10-µm circle with a single pulse of 473 nm light. Changes in the FRET efficiency (*E~corr~*) of the RhoA biosensor, indicative of RhoA activation, are shown in pseudocolor and as plots of average FRET efficiency within the irradiated circle (*blue*) and a nearby circle (*red*). In the PA-Rac1 cells, the irradiated spot showed bleaching of the biosensor followed by a relatively constant level of reduced RhoA activity. The nearby spot showed no bleaching, but a gradual decrease in RhoA activity reaching the low level achieved in the irradiated spot (n = 3 cells). In the control cells (C450M), the biosensor returned to near initial activation readouts after bleaching, and no change was seen in the nearby spot (n =3 cells). **b**, RhoA activation in constitutive pseudopods[@R8],[@R21] versus pseudopods induced by PA-Rac1 (473 nm, 20-µm circle shown, [Supplemental Movie S15](#SD1){ref-type="supplementary-material"}). The bar graph (**c**) shows the percent increase in biosensor FRET/CFP ratio in the region 1 micron from the cell edge versus the mean of the flat region at the left of the line scan. (means +/− 95% confidence intervals, 18 lines from 6 cells per bar).](nihms129300f3){#F3}

![Crystallization and structural modelling of PA-Rac1\
**a**, Dark state crystal structure of PA-Rac1. *Blue* = LOV domain, *red* = Jα helix, and *green* = Rac1. **b**, Interacting residues at the LOV-Rac interface (arrow in panel a), including Trp56. **c**, Mutating Cdc42 to include the Trp involved in stabilizing the LOV2-Rac1 interaction substantially improved LOV inhibition of Cdc42. Lane 1, PA-Cdc42; linking LOV to Cdc42 using the same truncations that produced good inhibition for Rac does not inhibit Cdc42-PAK binding. Lane 2, PA-Cdc42-CRIB; covalently linking the CRIB domain of PAK to PA-Cdc42 blocks PAK binding. Lane 3, PA-Cdc42-F56W; introduction of the tryptophan substantially improves LOV inhibition of Cdc42 binding to PAK. Lane 4, lit state mutant of PA-Cdc42-F56W, showing that Cdc42 inhibition is sensitive to the lit/dark state of the LOV domain. [Supplemental Movie S16 and Fig. S14](#SD1){ref-type="supplementary-material"} demonstrate the ability of PA-Cdc42-F56W to produce filopodia and protrusions in living cells.](nihms129300f4){#F4}
